Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

NCT07276789 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: LS301-IT 0.1 mg/kg

Sponsor

Integro Theranostics